This post was originally published on this site Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality called t(11;14) or with high levels of the cell survival protein BCL2, data from two studies suggest. Findings…
This post was originally published on this site First-line maintenance therapy with Bavencio (avelumab) failed to extend the overall survival of patients with advanced stomach or gastroesophageal junction (GEJ) cancer, as compared to standard care, according to the latest updates of the JAVELIN Gastric 100 clinical trial. The study was a Phase 3, multicenter, open-label…
This post was originally published on this site Weight loss surgery may reduce the risk of developing breast cancer in obese individuals, even among those with a genetic predisposition towards cancer, new research suggests. The research was presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting at ObesityWeek 2019, in a…
This post was originally published on this site INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead of targeting…
This post was originally published on this site A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…
This post was originally published on this site Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. Data from the clinical program of Ygalo and multiple myeloma’s impact on quality of life will be presented…
This post was originally published on this site Intermediate monocytes, a type of immune cell, may contribute to the development and progression of sarcoidosis through the production of TARC — a molecule that attracts other specific immune cells linked to inflammation, according to a small study. These findings point to intermediate monocytes and TARC as…
This post was originally published on this site The Bluefield Project to Cure FTD will receive $1.2 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to validate an exploratory blood test in frontotemporal dementia (FTD). The award is the first FTD investment through the foundation’s Diagnostics Accelerator, a venture philanthropy vehicle to advance the development of…
This post was originally published on this site Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. The companies plan to file an investigational new drug application for HPN217 with the U.S. Food and Drug…
This post was originally published on this site Treatment with Firdapse (Amifampridine phosphate) or Ruzurgi (3,4‐diaminopyridine, or 3,4‐DAP) is effective and well-tolerated among people with Lambert-Eaton myasthenic syndrome (LEMS), even in the presence of immunosuppressants or other medications that alter the responsiveness of the immune system, a review has found. The review study, “Amifampridine tablets…
